论文部分内容阅读
Ocular inflammatory diseases are responsible for up to 20 ％of all blindness.Corticosteroids,immunosuppressive agents and biologics targeting key inflammatory cytokines have been the major treatments for theses sight-threaten diseases.However,many patients are resistant or intolerant to current therapies.Using high-throughput sequencing technology,we recently defined the role of DNA methylation in inflammatory T cells and the microbiome in the eyes from patients with ocular diseases.We are therefore testing the novel treatments for these diseases.